Generic medicine buyers negotiating with Indian suppliers often hear one sentence that ends the discussion: “the price is fixed by the government.” That is only half true. In India, the National Pharmaceutical Pricing Authority (NPPA) fixes ceiling prices for a defined list of essential medicines under the Drugs (Prices Control) Order, 2013 (DPCO 2013). Everything else sits under a different rule — an annual cap on how much a manufacturer may increase the price, not a cap on the price itself.
For an international buyer, importer or hospital procurement team, understanding that distinction is not academic. It decides whether a quoted price is a regulated ceiling, a market price inside a monitored band, or a margin-capped price on a notified drug. This guide explains, in plain language, how each of the three mechanisms works, what the arithmetic looks like, and which questions to ask a supplier to confirm a quote is legitimate.
Quick note on timing: India’s Supreme Court questioned drug mark-ups in September 2026, and on 17 October 2026 NPPA capped trade margins on 137 anti-cancer medicines at 30%, effective 9 November 2026 (The Hindu, 2 November 2026). Those events matter for context, but they are separate mechanisms from the ceiling-price formula explained below.
🏛️ Two Regulators, Two Different Jobs
A frequent source of confusion is that India separates licensing from pricing. The Central Drugs Standard Control Organization (CDSCO) is responsible for approving drugs and enforcing quality standards. The National Pharmaceutical Pricing Authority handles what those approved drugs may cost. The two bodies operate under different statutes and, as commentators have noted, with limited coordination between them (The Hindu, 2 November 2026; BozokMedia, 2 November 2026).
| Authority | Primary mandate | Principal instrument |
|---|---|---|
| CDSCO | Licensing, approvals, quality and standards | Drugs and Cosmetics Act, 1940 & Rules, 1945 |
| NPPA | Price regulation and affordability | DPCO 2013 under the Essential Commodities Act, 1955 |
Practical implication for buyers: a manufacturer can hold a perfectly valid CDSCO licence and still be investigated by NPPA for overcharging. Verification of one does not verify the other. Buyers should check both independently.
💊 Scheduled vs Non-Scheduled: The First Fork
DPCO 2013 divides the market into two groups. Scheduled formulations are drugs listed in Schedule I of the order, drawn from the National List of Essential Medicines (NLEM). For these, NPPA fixes a ceiling price per unit — per tablet, per capsule, per millilitre or per gram, depending on dosage form. Non-scheduled formulations are everything else; they have no per-unit ceiling but are subject to an annual increase cap.
The split is uneven. Reporting in August 2026 put roughly 82% of medicines sold in India outside direct NPPA price control, a figure cited in parliamentary committee coverage that recommended a review of how medicines are categorised (Medical Dialogues, 11 August 2026; The South First, 9 August 2026). For buyers sourcing high-volume generics, that means the majority of products in a typical order are non-scheduled — and priced by the market, within limits.
One further nuance matters when checking a supplier’s claim: the NLEM is revised periodically (NLEM 2015, NLEM 2022 and subsequent updates are published by NPPA and the Ministry of Health). When a molecule is added to Schedule I, every pack size and dosage strength of that molecule must be brought within the ceiling with effect from the notification date. A quotation issued before a NLEM revision can therefore be compliant on the day it was signed and non-compliant shortly afterwards.
🧮 How the Ceiling Price Is Calculated — Market-Based Pricing
The core of DPCO 2013 is a market-based pricing method rather than a cost-plus method. Instead of asking each manufacturer what its product costs to make, NPPA looks at what the market was already charging for that molecule and derives a single ceiling from that data. The widely described sequence is:
- Identify the scheduled formulation — the specific molecule and dosage form listed in Schedule I.
- Collect market data for that formulation, using the moving annual turnover (MAT) values reported in the pharmaceutical market data available for the preceding period, covering brands with a meaningful market share.
- Select the reference brands — for formulations with a sufficiently large market, the ceiling is derived from the simple average of the prices of brands holding the leading market shares; the widely referenced threshold is the brands accounting for at least 1% of the total market turnover for that formulation.
- Compute the average price to retailer (PTR) across the selected brands, weighted by their market share.
- Add the permitted retailer margin to arrive at the ceiling price.
- Notify the ceiling by gazette notification, expressed per unit (tablet, capsule, ml, g).
Two qualifications, stated plainly because buyers rely on these numbers: the market-share threshold, the exact sampling window and the treatment of brands below the threshold are set out in the DPCO 2013 text and the explanatory memoranda attached to each ceiling notification. Where a formulation has very few brands or a very small market, NPPA’s approach differs from the mainstream case. Buyers who need the precise basis for a specific molecule should read that molecule’s own notification on the NPPA website rather than rely on a general description. [CITATION NEEDED] for the exact threshold language as applied to any individual molecule.
📐 From Ceiling to MRP: The Arithmetic Buyers Actually Use
A ceiling price is expressed per unit. A manufacturer’s maximum retail price is not. The bridge between the two is pack size plus permitted local taxes. The relationship that matters in day-to-day verification is:
Maximum MRP = (ceiling price per unit × number of units in the pack) + permitted local taxes
GST is treated as a permitted local tax over and above the ceiling, so a compliant MRP can legitimately exceed the plain ceiling-times-units figure. This is the single most common source of false alarm when a buyer cross-checks a quoted MRP against a published ceiling.
Worked example (illustrative arithmetic, not a specific product)
Suppose a scheduled formulation carries a ceiling of ₹10.00 per tablet and is sold in a strip of 10. Ceiling-times-units gives ₹100.00. Add GST at the applicable slab for that formulation and the permissible MRP rises accordingly. If a supplier’s quote for the same pack lands materially above that band, the buyer has a concrete question to ask. The numbers here are illustrative only — always substitute the actual notified ceiling for the actual molecule.
| Step | What you need | What it tells you |
|---|---|---|
| 1 | Notified ceiling price per unit (NPPA) | The regulated unit price |
| 2 | Units per pack | Converts unit price to pack price |
| 3 | Permitted local tax (GST slab) | The only legitimate addition above ceiling |
| 4 | Supplier’s quoted MRP | Compare against steps 2 + 3 |
📈 Non-Scheduled Drugs: The 10% Annual Increase Cap
Non-scheduled formulations have no ceiling, but they are not unregulated. Paragraph 20 of DPCO 2013 caps the increase in a manufacturer’s MRP at 10% in any preceding twelve-month period. NPPA monitors the cap, and a breach can trigger recovery proceedings. Because most medicines by volume sit outside Schedule I, this is the rule that governs the majority of generic quotations an international buyer will see.
Three practical points buyers should know:
- The 10% test applies to the per-pack MRP, not to the per-unit equivalent — a pack-size change alters the arithmetic and needs documentation.
- Compliance is tested at every pricing action, not once a year. A revision that lands at 9.8% is within cap; a subsequent revision in the same window that pushes past 10% is a breach.
- A supplier telling you “there is no price control on this product” is describing the ceiling, not the cap. The cap still applies.
⚠️ Compliance note: the 10% figure and the paragraph reference are the standard description of DPCO 2013 paragraph 20. Because the order has been amended since 2013, buyers relying on this for a contractual price-adjustment clause should verify the current text of the order rather than a secondary summary. [CITATION NEEDED] for amendment history.
🔗 Where Trade Margins Fit — and Where They Don’t
Ceiling price and trade margin are different levers, and conflating them is the second most common error. Under the ceiling-price system, the ceiling itself is built up from average price to retailer plus a permitted retailer margin — historically described as 16% for the retailer and 8% for the stockist on scheduled formulations, with variations under specific notifications.
Trade Margin Rationalisation (TMR) is a separate intervention used on notified drugs that are not handled through the ordinary ceiling mechanism. Instead of fixing a price, NPPA caps the margin between the first point of sale and the consumer. The October 2026 order capping trade margins at 30% on 137 anti-cancer medicines, effective 9 November 2026, is a TMR action (The Hindu, 2 November 2026; NPPA, “Revised MRP of Non-Scheduled Anti-Cancer Drugs — to be effective from 09/11/2026”). The 30% figure applies to the notified drugs only; it is not a general margin rule for Indian pharmaceuticals.
That distinction has real consequences for buyers. A quoted price on a TMR-notified cancer drug is constrained by the margin cap. A quoted price on an ordinary non-scheduled generic is constrained only by the 10% annual increase cap. The two look similar in a price list and are governed by entirely different provisions.
🛡️ Overcharging, Form V, and the Recovery Mechanism
When NPPA finds that a scheduled formulation has been sold above its ceiling, it issues a demand. The manufacturer responds with a Form V overcharging certificate quantifying the excess across SKUs, pack sizes and periods. The overcharged amount, plus interest, is recovered under Section 7A of the Essential Commodities Act and deposited into the Drugs Prices Equalisation Account (DPEA).
Scale is material. Reporting in August 2026 put outstanding medicine overcharging dues owed to the government at approximately ₹8,526 crore, with a parliamentary panel calling for a dedicated NPPA legal cell (Medical Dialogues, 10 August 2026). In September 2026 the Bombay High Court quashed an NPPA pricing order and a ₹13.41 crore recovery demand against Pharmed, holding that a ceiling cannot be imposed without following the DPCO mechanism (Live Law, 26 September 2026; Medical Dialogues, 26 September 2026). Subsequent reporting indicates NPPA may re-examine such demands.
For buyers, the signal is that a price notification is not automatically final. Enforcement is litigated, and some demands are set aside. That cuts both ways: a supplier’s assertion that a demand was “overturned in court” may be true for that supplier and irrelevant to the compliance of your consignment.
✅ A Six-Point Verification Checklist for Buyers
Use this list before accepting a quotation on any Indian generic medicine. Each point maps to one of the mechanisms above.
- ✅ Confirm scheduling status. Ask the supplier, in writing, whether the molecule is a scheduled formulation under Schedule I of DPCO 2013 (based on NLEM). Do not accept a verbal answer.
- ✅ Pull the notified ceiling. Look up the molecule’s ceiling price on the NPPA website and check the notification date is current — ceilings are revised, typically with effect from 1 April each year on a WPI-linked basis.
- ✅ Do the arithmetic. Ceiling per unit × units per pack, then add the applicable GST slab. Compare that band against the quoted MRP.
- ✅ For non-scheduled molecules, ask for the prior MRP. A supplier should be able to show the MRP twelve months earlier to demonstrate the year-on-year increase sits inside the 10% cap.
- ✅ Separate TMR products from ceiling products. If the product is a notified drug under Trade Margin Rationalisation, the governing rule is the margin cap, not the ceiling. Confirm which applies.
- ✅ Verify the supplier, not just the price. Price compliance says nothing about manufacturing quality. Cross-check the manufacturer’s CDSCO licence and WHO-GMP status, and for sourcing, refer to IMSDA’s verified member directory for a list of verified and reliable pharmaceutical distributors.
❓ Frequently Asked Questions
Is the ceiling price the same as the MRP?
No. The ceiling is a per-unit regulated price. MRP for a pack is the ceiling multiplied by the number of units in the pack, plus permitted local taxes such as GST. A quoted MRP above the bare ceiling-times-units figure is not automatically a violation.
Does a scheduled drug’s price ever increase?
Yes. Ceiling prices are revised annually using the Wholesale Price Index for the preceding year, typically effective 1 April. The revision is a maximum permissible change, not a mandate, so a manufacturer may hold prices flat in competitive segments.
Are most Indian generic medicines price-controlled?
By count of medicines sold, no. August 2026 reporting indicated roughly 82% of medicines in the Indian market sit outside direct NPPA price control — they are non-scheduled and subject only to the 10% annual increase cap (Medical Dialogues, 11 August 2026).
Why does the same molecule cost different amounts from different manufacturers?
For scheduled formulations, all brands must stay within the same ceiling, so differences should be small. For non-scheduled formulations, the market sets the price and brands can differ widely, constrained only by the annual increase cap. Mixing the two categories when benchmarking quotations produces misleading conclusions.
🎯 Final Thoughts
The Indian system is not one price control but three overlapping ones: a per-unit ceiling for scheduled essential medicines, a 10% annual increase cap for the rest, and margin caps on specifically notified drugs. Nearly all confusion in buyer-supplier price conversations comes from applying the wrong one to the wrong product.
The practical approach is simple. Establish the scheduling status first, pull the notified ceiling or the prior-year MRP second, and only then evaluate the quote. A supplier who can answer those questions clearly, with documents, is usually a supplier worth a longer conversation. For a list of verified and reliable pharmaceutical distributors, refer to IMSDA’s verified member directory.
For more information, contact IMSDA at contact@indiamedicine.org.
📚 Sources
- NPPA, “Revised MRP of Non-Scheduled Anti-Cancer Drugs — to be effective from 09/11/2026”, nppa.gov.in
- The Hindu, “Who decides the cost of medicines in India?”, 2 November 2026 — Supreme Court observation on a ₹2,700-to-₹27,000 cancer drug mark-up; 30% trade margin cap on 137 anti-cancer drugs effective 9 November 2026; separation of CDSCO licensing and NPPA pricing.
- BozokMedia, “Who Decides the Cost of Medicines in India?”, 2 November 2026 — CDSCO vs NPPA mandate table; 1962 Defence of India Act origin of statutory drug price control.
- NPPA, Drugs (Prices Control) Order, 2013 — Schedule I scheduling, paragraph 20 annual increase cap, Form V overcharging certification.
- Medical Dialogues, “82% Medicines Outside NPPA’s Direct Price Control, Govt Panel Seeks Pricing Framework Review”, 11 August 2026.
- The South First, “8 in 10 medicines sold in India are outside government price control, Parliament seeks policy review”, 9 August 2026.
- Medical Dialogues, “Pharma Firms Owe Govt Rs 8,526 Crore in Medicine Overcharging Dues, Panel Seeks NPPA Legal Cell”, 10 August 2026.
- Live Law, “NPPA Cannot Impose Blanket Price Ceiling Without Following DPCO Mechanism: Bombay High Court Quashes 2009…”, 26 September 2026.
- Medical Dialogues, “Bombay HC Quashes NPPA Pricing Order, Blocks Rs 13.41 Cr Recovery Against Pharmed”, 26 September 2026.